Yoshida / Hagihara / Ebashi CNS Pharmacology Neuropeptides

Proceedings of the 8th International Congress of Pharmacology, Tokyo, 1981
1. Auflage 2013
ISBN: 978-1-4831-4844-1
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 296 Seiten, Web PDF

Advances in Pharmacology and Therapeutics II, Volume 1: CNS Pharmacology Neuropeptides contains the proceedings of the Eighth International Congress of Pharmacology held in Tokyo in 1981. This book is the first of a six-volume compilation of the scientific papers of invited speakers. Separating 26 papers as chapters, this book begins with an invited lecture on opioid peptides and their receptors. Other chapters describe opioid peptides and their relevance to central nervous system mechanisms; neuropeptides and related compounds affecting learning and memory; and pharmacological approaches to the study of sleep regulation. This book also explores the importance of kainic acid and related compounds as a pharmacological tool.

Autoren/Hrsg.

Yoshida, H.

Hagihara, Y.

Ebashi, S.

Inhaltsverzeichnis

1;Front Cover;1
2;CNS Pharmacology
Neuropeptides;4
3;Copyright Page;5
4;Table of Contents;6
5;Introduction;10
6;PART 1: INVITED LECTURE;12
6.1;Chapter 1. Opioid Peptides and their Receptors;14
6.1.1;ABSTRACT;14
6.1.2;KEYWORDS;14
6.1.3;INTRODUCTION;14
6.1.4;HETEREOGENEITY OF OPIATE RECEPTORS;15
6.1.5;EPILOGUE;23
6.1.6;REFERENCES;23
7;PART 2: SYMPOSIUM Opioid Peptides and their Relevance for CNS Mechanisms;26
7.1;Chapter 2. Role of "Enkephalinase" (Enkephalin- Dipeptidylcarboxypeptidase) as Synaptic Neuropeptidase;28
7.1.1;ABSTRACT;28
7.1.2;INTRODUCTION;28
7.1.3;PROPERTIES OF "ENKEPHALINASE" AND PROPOSED MODEL FOR ITS ACTIVE SITE.;29
7.1.4;LOCALISATION OF "ENKEPHALINASE";31
7.1.5;EFFECTS OF THIORPHAN, AN ENKEPHALINASE INHIBITOR;34
7.1.6;CONCLUSION : CRITERIA FOR THE IDENTIFICATION OF A SYNAPTIC NEUROPEPTIDASE;35
7.1.7;REFERENCES;37
7.2;Chapter 3. Opioid Peptides and Analgesia: Sites of Action;40
7.2.1;ABSTRACT;40
7.2.2;KEYWORDS;40
7.2.3;INTRODUCTION;40
7.2.4;SUMMARY;47
7.2.5;ACKNOWLEDGEMENTS;48
7.2.6;REFERENCES;48
7.3;Chapter 4. Intrathecal Use of Beta-Endorphin as a Powerful Analgetic Agent in Man;50
7.3.1;ABSTRACT;50
7.3.2;KEYWORDS;50
7.3.3;INTRODUCTION;50
7.3.4;RELIEF OF CANCER PAIN;50
7.3.5;METHOD:;50
7.3.6;RESULTS;51
7.3.7;ß-ENDORPHIN FOR OBSTETRICAL ANALGESIA MATERIALS AND METHODS:;52
7.3.8;RESULTS:;53
7.3.9;DISCUSSION:;53
7.3.10;REFERENCES;54
7.4;Chapter 5. Endorphins and Thyrotropin Releasing Hormone in Shock and Trauma;56
7.4.1;ABSTRACT;56
7.4.2;KEYWORDS;56
7.4.3;INTRODUCTION;56
7.4.4;ENDOTOXIC SHOCK;57
7.4.5;HEMORRHAGIC SHOCK;58
7.4.6;SPINAL TRAUMA;60
7.4.7;ENDOCRINE INVOLVEMENT;61
7.4.8;AUTONOMIC INVOLVEMENT;62
7.4.9;THYROTROPIN RELEASING HORMONE IN SHOCK;63
7.4.10;REFERENCES;63
7.5;Chapter 6. Endorphins — Clinical Relevance in Neurology;68
7.5.1;ABSTRACT;68
7.5.2;KEYWORDS;68
7.5.3;INTRODUCTION;69
7.5.4;REFERENCES;76
7.6;Chapter 7. On the Role of Endorphins in Addiction;78
7.6.1;ABSTRACT;78
7.6.2;KEYWORDS;78
7.6.3;INTRODUCTION;78
7.6.4;CONCLUSIONS;84
7.6.5;ACKNOWLEDGEMENT;85
7.6.6;REFERENCES;85
8;PART 3: INVITED LECTURE Critical Review of Pain Relieving Procedures Including Acupuncture;88
8.1;Chapter 8. Critical Review of Pain Relieving Procedures Including Acupuncture;90
8.1.1;ABSTRACT;90
8.1.2;KEYWORDS;90
8.1.3;INTRODUCTION;90
8.1.4;ANALGESIA AND THE MULTIPLE DESCENDING INHIBITORY SYSTEMS;91
8.1.5;A. THE NRGC NRPG-SPINAL NORADRENERGIC SYSTEM;92
8.1.6;B. THE PAG-NRM-SPINAL SEROTONERGIC SYSTEM;94
8.1.7;C. THE OPIOIDERGIC SYSTEMS;96
8.1.8;D. ACUPUNCTURE ANALGESIA;99
8.1.9;REFERENCE;100
9;PART 4: SYMPOSIUM Substance P;104
9.1;Chapter 9. Substance P-Mediated Synaptic Excitation in Mammalian Spinal Cord and Sympathetic Ganglia;106
9.1.1;ABSTRACT;106
9.1.2;KEYWORDS;106
9.1.3;INTRODUCTION;106
9.1.4;IDENTIFICATION BY HPLC OF IMMUNOREACTIVE SP RELEASED FROM RAT SPINAL CORD;107
9.1.5;SP IN THE SYMPATHETIC GANGLIA OF THE GUINEA PIG;108
9.1.6;ENKEPHALINERGIC PRESYNAPTIC INHIBITION ON SP SYNAPSE;111
9.1.7;PEPTIDERGIC SYNAPSES IN SYMPATHETIC GANGLIA;111
9.1.8;CONCLUSIONS;112
9.1.9;REFERENCES;112
9.2;Chapter 10. Substance P in the Intestine;114
9.2.1;ABSTRACT;114
9.2.2;KEYWORDS;114
9.2.3;INTRODUCTION;114
9.2.4;DISTRIBUTION AND ORIGIN OF SUBSTANCE P-CONTAINING NEURONS IN THE INTESTINE;116
9.2.5;PROJECTIONS OF THE ENTERIC SUBSTANCE P IMMUNOREACTIVE NEURONS;117
9.2.6;RELEASE OF SUBSTANCE P FROM INTESTINAL NERVES;118
9.2.7;THE SITES OF ACTION OF SUBSTANCE P IN THE INTESTINE;120
9.2.8;NERVE PATHWAYS WHICH INVOLVE SUBSTANCE P-CONTAINING NEURONS;120
9.2.9;REFERENCES;121
9.3;Chapter 11. Substance P and the Primary Afferent Neuron;126
9.3.1;ABSTRACT;126
9.3.2;KEYWORDS;126
9.3.3;Introduction;126
9.3.4;Afferent peptidergic neurons;127
9.3.5;Substance P in small diameter primary afferents;127
9.3.6;Capsaicin;128
9.3.7;Central nerve endings;129
9.3.8;Interaction with opiates;130
9.3.9;Peripheral nerve endings;131
9.3.10;Involvement of histamine;132
9.3.11;Somatostatin;132
9.3.12;Axon reflex;132
9.3.13;REFERENCES;133
10;PART 5: INVITED LECTURE Inhibition of Prolactin Secretion;138
10.1;Chapter 12. Inhibitors of Prolactin Secretion;140
10.1.1;ABSTRACT;140
10.1.2;KEYWORDS;140
10.1.3;INTRODUCTION;140
10.1.4;I THE PHYSIOLOGICAL BASIS;141
10.1.5;II INHIBITORS OF PROLACTIN SECRETION;141
10.1.6;Ill COMMENTS;150
10.1.7;REFERENCES;151
11;PART 6: INVITED LECTURE Anorectic Agents and Satietin, an Endogenous Inhibitor of Food Intake;156
11.1;Chapter 13. Anorectic Agents and Satietin, an Endogenous Inhibitor of Food Intake;158
11.1.1;ABSTRACT;158
11.1.2;KEYWORDS;158
11.1.3;REFERENCES;171
12;PART 7: SYMPOSIUM Neuropeptides and Related Compounds Affecting Learning and Memory;174
12.1;Chapter 14. Neuropeptides and Emotional Behavior;176
12.1.1;ABSTRACT;176
12.1.2;KEYWORDS;176
12.1.3;INTRODUCTION;176
12.1.4;BEHAVIORAL EFFECT;177
12.1.5;NEUROCHEMICAL EFFECTS;180
12.1.6;REFERENCES;183
12.2;Chapter 15. Neurohypophyseal Hormones and Memory;186
12.2.1;ABSTRACT;186
12.2.2;KEY WORDS;186
12.2.3;OPPOSITE INFLUENCES OF VASOPRESSIN AND OXYTOCIN ON MEMORY PROCESSES;186
12.2.4;STRUCTURE-ACTIVITY STUDIES WITH PEPTIDE FRAGMENTS AND ANALOGS;188
12.2.5;MODE OF ACTION OF NEUROHYPOPHYSEAL PEPTIDES ON MEMORY PROCESSES;191
12.2.6;NEUROHYPOPHYSEAL PEPTIDES AND HUMAN MEMORY DISORDERS;193
12.2.7;REFERENCES;194
12.3;Chapter 16. Neuropeptides and Morphine Tolerance;200
12.3.1;ABSTRACT;200
12.3.2;KEYWORDS;200
12.3.3;METHODS;201
12.3.4;RESULTS;201
12.3.5;CONCULSIONS;207
12.3.6;ACKNOWLEDGEMENTS;208
12.3.7;REFERENCES;208
12.4;Chapter 17. Neurohypophyseal Hormones and Addiction;210
12.4.1;ABSTRACT;210
12.4.2;KEYWORDS;210
12.4.3;INTRODUCTION;210
12.4.4;EXPERIMENTAL ADDICTION (TEST SYSTEM);211
12.4.5;OTHER ROUTES OF DG-AVP ADMINISTRATION;214
12.4.6;PHYSIOLOGICAL INVOLVEMENT OF VASOPRESSIN;215
12.4.7;STRUCTURE ACTIVITY RELATIONSHIPS;217
12.4.8;HEROIN ADDICTS;217
12.4.9;MODE OF ACTION;218
12.4.10;CONCLUDING REMARKS;219
12.4.11;REFERENCES;219
13;PART 8: SYMPOSIUM Pharmacological Approaches to the Study of Sleep Regulation;222
13.1;Chapter 18. Sleep as a Dynamic Process;224
13.1.1;ABSTRACT;224
13.1.2;KEYWORDS;224
13.1.3;REFERENCES;227
13.2;Chapter 19. Purification of Sleep-Promoting Substances (SPS);228
13.2.1;ABSTRACT;228
13.2.2;KEYWORDS;228
13.2.3;KEYWORDS FOR SUBJECT INDEX;228
13.2.4;INTRODUCTION;228
13.2.5;EXTRACTION OF SLEEP-PROMOTING SUBSTANCES (SPS);229
13.2.6;PURIFICATION OF SLEEP-PROMOTING SUBSTANCES (SPS);230
13.2.7;THE RAT BIOASSAY OF SLEEP-PROMOTING SUBSTANCES (SPS);231
13.2.8;ACKNOWLEDGEMENT;237
13.2.9;REFERENCES;237
13.3;Chapter 20. The Search for Circulating Sleep-Promoting Factors;238
13.3.1;ABSTRACT;238
13.3.2;KEYWORDS;238
13.3.3;INTRODUCTION;238
13.3.4;SUBSTANCES FROM SLEEP-DEPRIVED ANIMALS.;239
13.3.5;SUBSTANCES ASSOCIATED WITH SLEEP OR NIGHTTIME;241
13.3.6;DISCUSSION;246
13.3.7;REFERENCES;249
13.4;Chapter 21. Voltammetric Detection of Brain 5-Hydroxyindolacetic Acid Fluctuations During the Sleep-Walking Cycle;252
13.4.1;ABSTRACT;252
13.4.2;KEYWORDS;252
13.4.3;INTRODUCTION;252
13.4.4;METHODS;253
13.4.5;RESULTS AND DISCUSSION;253
13.4.6;ACKNOWLEDGEMENT;254
13.4.7;REFERENCES;254
13.5;Chapter 22. Neuropharmacological Tests of the Reciprocal Interaction Model of Sleep Cycle Control;258
13.5.1;ABSTRACT;258
13.5.2;KEYWORDS;258
13.5.3;INTRODUCTION;258
13.5.4;REVIEW OF EMPIRICAL PHARMACOLOGICAL EVIDENCE;259
13.5.5;METHODOLOGICAL PROBLEMS AND RESULTS OF ATTEMPTS TO SOLVE THEM;259
13.5.6;TOWARD A CELLULAR NEUROPHARMACOLOGY OF SLEEP STATE CONTROL;262
13.5.7;ACKNOWLEDGEMENT;263
13.5.8;REFERENCES;263
14;PART 9: WORKSHOP Kainic Acid and Related Compounds as a Pharmacological Tool;266
14.1;Chapter 23. Actions of Kainic Acid and Related Analogues on Hirudo, Helix and Limulus Central Neurones;268
14.1.1;ABSTRACT;268
14.1.2;KEYWORDS;268
14.1.3;INTRODUCTION;268
14.1.4;RESULTS AND DISCUSSION;269
14.1.5;ACKNOWLEDGEMENT;273
14.1.6;REFERENCES;273
14.2;Chapter 24. A Comparison Between the Glutamate Response and the Excitatory Junctional Potential in the Presence of Kainic Acid at the Crayfish Neuromuscular Junction;276
14.2.1;ABSTRACT;276
14.2.2;KEYWORDS;276
14.2.3;INTRODUCTION;276
14.2.4;METHODS;277
14.2.5;RESULTS;277
14.2.6;DISCUSSION;280
14.2.7;REFERENCES;281
14.3;Chapter 25. Kainic Acid: Neurotoxicity and Receptor Interactions;282
14.3.1;INTRODUCTION;282
14.3.2;RESULTS;282
14.3.3;DISCUSSION;285
14.3.4;ACKNOWLEDGEMENT;287
14.3.5;REFERENCES;287
14.4;Chapter 26. A Possible Mechanism for Excitant Amino Acid Toxicity;288
14.4.1;ABSTRACT;288
14.4.2;KEYWORDS;288
14.4.3;INTRODUCTION;288
14.4.4;METHODS;289
14.4.5;RESULTS;289
14.4.6;CONCLUSIONS;290
14.4.7;REFERENCES;291
15;Index;294